Updated:
Eli Lilly & Company
Eli Lilly & Company has existed since Colonel Eli Lilly opened a drug manufacturing plant in Indianapolis in 1876, making it one of the oldest continuously...
Eli Lilly & Company
Eli Lilly & Company has existed since Colonel Eli Lilly opened a drug manufacturing plant in Indianapolis in 1876, making it one of the oldest continuously operating pharmaceutical enterprises in the United States. The firm remains headquartered in Indianapolis, where Ricks — Chair, President, and CEO — oversees a publicly traded entity whose market capitalization has surpassed $700 billion on the strength of its diabetes and obesity portfolio. A significant block of stock — roughly 10.8% — is held by the Lilly Endowment Inc., a separate philanthropic foundation created by the Lilly family that operates as an independent entity with its own grant-making and investment strategy. The investment office, run by Chief Investment Officer Susan Ridlen, directs capital across multiple asset classes including the U.S. pension portfolio, real estate tied to manufacturing and R&D sites, and strategic venture partnerships in life sciences. The firm has co-invested alongside TVM Capital Life Science in innovation-focused funds, reflecting a posture of backing external venture managers whose work aligns with therapeutic areas relevant to Lilly's pipeline. Directly held real estate spans manufacturing campuses in Indiana, Texas, Alabama, Wisconsin, and Suzhou, China, alongside biotechnology research space in San Diego — assets deployed in service of the company's branded drug production rather than a standalone real-estate fund strategy. Ridlen's team operates within the corporate treasury function, deploying defined-benefit pension capital and corporate cash through a diversified strategy that covers hedge fund allocations, private credit, and secondaries. The firm's pension portfolio is run from Indianapolis, and while total investment assets are not separately disclosed from the parent company's balance sheet, the scale of Lilly's market capitalization and its manufacturing infrastructure implies a multi-billion-dollar deployable pool. The investment office has maintained a deliberately low profile, with no outward marketing to external limited partners. What distinguishes this investment operation structurally is its symbiotic tie to the parent pharmaceutical company's operational footprint and the separate, but historically linked, Lilly Endowment. Unlike a sovereign wealth fund or a standalone family office, the Eli Lilly investment office manages capital that is embedded in a Fortune 500 corporate treasury, yet it shares a founder and a legacy shareholder relationship with one of the largest philanthropic endowments in the United States — a dual structure that creates unusual co-investment and signaling dynamics in the life-sciences venture ecosystem.
General information
Firm type
Corporate Investor
Year founded
1876
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
Indianapolis, IN, United States
Additional offices
San Diego, CA · Houston, TX · Huntsville, AL · Pleasant Prairie, WI · Suzhou, China
Principals
David A. Ricks
Chair, President, and CEO
Susan Ridlen
Chief Investment Officer, Eli Lilly Investment Office
Sector focus
Frequently asked questions
Who runs investment decisions at Eli Lilly & Company?
Susan Ridlen serves as Chief Investment Officer of the Eli Lilly Investment Office and leads day-to-day capital deployment across the pension portfolio, strategic venture commitments, and corporate cash management. She operates within the treasury function of the parent company, reporting through the corporate finance leadership chain. David Ricks, as Chair and CEO, sets the overall capital-allocation framework at the board level.
How is the Lilly Endowment related to the company's investment office?
The Lilly Endowment is a separate, independent philanthropic entity that holds approximately 10.8% of Eli Lilly and Company's publicly traded stock — a legacy of the founding Lilly family. While the Endowment manages its own investment portfolio with its own staff and governance, the two share historical founders and the Endowment's equity stake creates a structural overlap in long-term economic interests. The company's corporate investment office does not manage the Endowment's assets.
Does Eli Lilly participate in venture capital investing?
Yes — the firm has a strategic partnership with TVM Capital Life Science, a venture capital firm focused on life-science innovation investments. These co-investment relationships allow Lilly to gain early exposure to therapeutic platforms and drug-development technologies that may complement its internal pipeline, though the investment office does not function as a standalone venture capital firm.
What types of real estate does Eli Lilly hold as investments?
Lilly's real-estate holdings are primarily operational rather than investment-grade rent-generating properties. The portfolio includes manufacturing facilities in Indianapolis, Houston, Huntsville, Pleasant Prairie, Wisconsin, and Suzhou, China, along with the Lilly Biotechnology Center in San Diego. These sites serve the company's drug production and research mandate rather than a diversified real-estate fund strategy.
What is the known posture on co-investments alongside external GPs?
Lilly has demonstrated willingness to co-invest alongside external fund managers, as evidenced by its strategic relationship with TVM Capital Life Science. The investment office operates with a flexible mandate that can accommodate direct co-investments when they align with the company's strategic interests, though it does not publicly solicit co-investment opportunities from external managers.
Is the pension portfolio managed in-house or outsourced?
The Eli Lilly pension portfolio is managed by the internal investment office under Susan Ridlen from Indianapolis. The team handles asset allocation and manager selection across multiple strategies including hedge funds, private credit, and secondaries, though specific external manager relationships are not publicly disclosed.
Where does Eli Lilly's underlying capital come from?
The capital managed by the investment office originates from the parent pharmaceutical company's operating cash flows and defined-benefit pension obligations. Eli Lilly generates revenue through the sale of branded pharmaceuticals — most significantly in diabetes, oncology, and immunology — with recent growth driven by incretin-based obesity and diabetes drugs that have pushed market capitalization above $700 billion.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: